Stargazer Pharmaceuticals, Inc., is a Boston-based biopharmaceutical drug development company launched in 2018 with a focus on rare diseases of the eye, and an initial focus on Stargardt Disease.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/09/20 | $57,000,000 | Series A |
Canaan Partners Novo Holdings Pontifax Retinal Degeneration Fund VenBio | undisclosed |
